Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 5.88mg equivalent to estradiol 5.69 mg (75µg/24h) excipient: acrylates copolymer ethyl oleate glyceryl monolaurate isopropyl myristate - for short-term treatment of complaints associated with the menopause and post-menopause, including signs and symptoms of oestrogen deficiency, whether naturally or surgically induced. oestrogen replacement therapy in women with an intact uterus should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals. prevention of postmenopausal osteoporosis.

Singapoo - Kiingereza - HSA (Health Sciences Authority)

pfizer private limited - conjugated estrogens (ce) desiccation with lactose @4.29% ce - tablet, sugar coated - 0.3 mg - conjugated estrogens (ce) desiccation with lactose @4.29% ce 0.3 mg

Singapoo - Kiingereza - HSA (Health Sciences Authority)

pfizer private limited - conjugated estrogens desiccation with lactose 14.57mg @4.29% ce - tablet, sugar coated - 0.625 mg - conjugated estrogens desiccation with lactose 14.57mg @4.29% ce 0.625 mg

Kanada - Kiingereza - Health Canada

novo nordisk canada inc - estradiol; norethindrone acetate - tablet - 0.5mg; 0.1mg - estradiol 0.5mg; norethindrone acetate 0.1mg - progestins

Marekani - Kiingereza - NLM (National Library of Medicine)

meda pharmaceuticals inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.52 mg in 0.87 g -     elestrin is contraindicated in women with any of the following conditions: risk summary elestrin is not indicated for use in pregnancy. there are no data with the use of elestrin in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies or limb-reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy. animal studies to evaluate embryo/fetal toxicity were not conducted with elestrin. risk summary estrogens are present in human milk and can reduce milk production in breast-feeding women. this reduction can occur at any time but is less likely to occur once breast-feeding is well-established. the developmental and health benefits of breast-feeding should be considered along with the mother’s clinical need for elestrin and any potential adverse effects on the breast-fed child from elestrin or from the underlying maternal condition. elestrin is not indicated in pediatric patients. clinical studies have not been conducted in the pediatric population. there have not been sufficient numbers of geriatric women involved in clinical studies utilizing elestrin to determine whether those over 65 years of age differ from younger subjects in their response to elestrin. in the whi estrogen-alone substudy (daily ce [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies (14.2)] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies (14.2)] . in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.3), and clinical studies (14.3)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8  [see warnings and precautions (5.3), and clinical studies (14.3)] . elestrin® (el-les-strin) (estradiol gel) figure 1 to apply the dose, hold the pump with the tip facing the application area of the arm. for each pump depression needed, press the pump firmly and fully with a continuous motion without hesitation. figure 2 gently spread the gel using only 2 fingers. spread and gently rub in the gel over the entire area of your upper arm and shoulder area, as illustrated. elestrin should not be used after the date printed on the container (expiration date). what are the ingredients in elestrin? active ingredient: estradiol. inactive ingredients: purified water, ethanol, propylene glycol, diethylene glycol monoethyl ether, carbomer homopolymer type c, triethanolamine, and edetate disodium. elestrin is a registered trademark of meda pharma s.a.r.l., a viatris company. distributed by: meda pharmaceuticals inc. canonsburg, pa 15317 u.s.a. © 2024 viatris inc. rev. 12/2023 in-0480-08 141343-1223

Marekani - Kiingereza - NLM (National Library of Medicine)

physicians total care, inc. - estradiol cypionate (unii: 7e1dv054lo) (estradiol cypionate - unii:7e1dv054lo) - estradiol cypionate 5 mg in 1 ml - depo-estradiol injection is indicated in the treatment of: - moderate to severe vasomotor symptoms associated with the menopause. - hypoestrogenism due to hypogonadism. estrogens should not be used in individuals with any of the following conditions: - undiagnosed abnormal genital bleeding. - known or suspected cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - depo-estradiol should not be used in patients with known hypersensitivity to its ingredients. - known or suspected pregnancy. there is no indication for depo-estradiol in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions.) chlorobu

Marekani - Kiingereza - NLM (National Library of Medicine)

physicians total care, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - femhrt is indicated in women with an intact uterus for the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. non-estrogen medications should be carefully considered. the mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin d intake, and when indicated, pharmacologic therapy. postmenopausal women require an average of 1500 mg/day of elemental calcium. therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. vitamin d supplementation of 400-800 iu/day may also be required to ensure adequate daily intake in postmenopausal women. risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previou

Marekani - Kiingereza - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - estradiol 1 mg -   limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered. amabelz is contraindicated in women with any of the following conditions:     •    undiagnosed abnormal genital bleeding     •    known, suspected, or history of breast cancer     •    known, past or suspected estrogen-dependent neoplasia     •    active dvt, pe, or history of these conditions     •    active arterial thromboembolic disease (for example stroke and mi), or a history of these conditions     •    known anaphylactic reaction or angioedema or hypersensitivity to amabelz     •    known liver impairment or disease     •    known protein c, protein s, or antithrombin deficiency, or other

Marekani - Kiingereza - NLM (National Library of Medicine)

breckenridge pharmaceutical, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 1 mg - estradiol/norethindrone acetate tablets are indicated for:   limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. estradiol/norethindrone acetate tablets are contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding [see warnings and precautions (5.2)] - breast cancer or history of breast cancer [see warnings and precautions (5.2)] - estrogen-dependent neoplasia [see warnings and precautions (5.2)] - active dvt, pe, or history of these conditions [see warnings and precautions (5.1)] - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions [see warnings and precauti

Marekani - Kiingereza - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol 1 mg - mimvey is indicated for: limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. mimvey is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding [see warnings and precautions (5.2 )] - breast cancer or history of breast cancer [see warnings and precautions (5.2)] - estrogen-dependent neoplasia [see warnings and precautions (5.2 )] - active dvt, pe, or history of these conditions [see warnings and precautions (5.1)] - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions [see warnings and precautions (5.1 )] - known anaphylactic reaction, angioedema, or hypersensi